NM_015340.4:c.2572C>A

Variant summary

Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong

The NM_015340.4(LARS2):​c.2572C>A​(p.Gln858Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000453 in 1,612,044 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000049 ( 0 hom. )

Consequence

LARS2
NM_015340.4 missense

Scores

19

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:1

Conservation

PhyloP100: 0.713
Variant links:
Genes affected
LARS2 (HGNC:17095): (leucyl-tRNA synthetase 2, mitochondrial) This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyl-tRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a specific tRNA or tRNA isoaccepting family with the cognate amino acid. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.052877933).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LARS2NM_015340.4 linkc.2572C>A p.Gln858Lys missense_variant Exon 22 of 22 ENST00000645846.2 NP_056155.1 Q15031
LARS2NM_001368263.1 linkc.2572C>A p.Gln858Lys missense_variant Exon 21 of 21 NP_001355192.1
LARS2XM_017006042.2 linkc.*29C>A 3_prime_UTR_variant Exon 21 of 21 XP_016861531.1
LARS2XM_047447830.1 linkc.*29C>A 3_prime_UTR_variant Exon 20 of 20 XP_047303786.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LARS2ENST00000645846.2 linkc.2572C>A p.Gln858Lys missense_variant Exon 22 of 22 NM_015340.4 ENSP00000495093.1 Q15031

Frequencies

GnomAD3 genomes
AF:
0.0000131
AC:
2
AN:
152184
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000282
AC:
7
AN:
248598
Hom.:
0
AF XY:
0.0000297
AC XY:
4
AN XY:
134478
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000554
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000531
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000486
AC:
71
AN:
1459742
Hom.:
0
Cov.:
31
AF XY:
0.0000523
AC XY:
38
AN XY:
726256
show subpopulations
Gnomad4 AFR exome
AF:
0.000421
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000351
Gnomad4 OTH exome
AF:
0.000166
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152302
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74480
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.00000378
ExAC
AF:
0.0000494
AC:
6
EpiCase
AF:
0.0000546
EpiControl
AF:
0.00

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:3
Dec 11, 2020
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Observed in a patient with suspected mitochondrial disease in published literature (Nogueira et al., 2019); however, this patient did not have hearing loss; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 30831263) -

Dec 02, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces glutamine, which is neutral and polar, with lysine, which is basic and polar, at codon 858 of the LARS2 protein (p.Gln858Lys). This variant is present in population databases (rs777893707, gnomAD 0.006%). This missense change has been observed in individual(s) with clinical features of LARS2-related conditions (PMID: 30831263, 36099812). ClinVar contains an entry for this variant (Variation ID: 505168). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt LARS2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Mar 12, 2021
Revvity Omics, Revvity
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Uncertain:1
Jun 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant classified as Uncertain Significance - Favor Benign. The p.Gln858Lys var iant in LARS2 has not been previously reported in individuals with hearing loss, but has been identified in 6/66474 European chromosomes by the Exome Aggregatio n Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs777893707). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. The glutamine (Gln) residue at position 8 58 is not conserved in mammals or evolutionarily distant species and one mammal (tenrec) carries a lysine (Lys), supporting that the change at this position may be tolerated. Additional computational prediction tools suggest that the p.Gln 858Lys variant may not impact the protein, though this information is not predic tive enough to rule out pathogenicity. In summary, while the clinical significan ce of the p.Gln858Lys variant is uncertain, available data suggest that it is mo re likely to be benign. -

Inborn genetic diseases Uncertain:1
May 13, 2022
Ambry Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.2572C>A (p.Q858K) alteration is located in exon 22 (coding exon 20) of the LARS2 gene. This alteration results from a C to A substitution at nucleotide position 2572, causing the glutamine (Q) at amino acid position 858 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Perrault syndrome 4;C4310761:Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome Benign:1
Sep 20, 2024
3billion
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The homozygous variant was found in patients diagnosed with another variant in a different gene, with no symptoms related to the gene containing the homozygous variant. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.079
BayesDel_addAF
Benign
-0.40
T
BayesDel_noAF
Benign
-0.64
CADD
Benign
13
DANN
Benign
0.90
DEOGEN2
Benign
0.12
T;T;.;T;T
Eigen
Benign
-0.60
Eigen_PC
Benign
-0.57
FATHMM_MKL
Benign
0.44
N
LIST_S2
Benign
0.69
.;.;T;.;T
M_CAP
Benign
0.0056
T
MetaRNN
Benign
0.053
T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.6
L;L;.;L;L
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-0.67
N;N;N;.;.
REVEL
Benign
0.048
Sift
Benign
0.80
T;T;T;.;.
Sift4G
Benign
0.85
T;T;T;.;.
Polyphen
0.042
B;B;B;B;B
Vest4
0.076
MutPred
0.45
Gain of methylation at Q858 (P = 0.0078);Gain of methylation at Q858 (P = 0.0078);.;Gain of methylation at Q858 (P = 0.0078);Gain of methylation at Q858 (P = 0.0078);
MVP
0.38
MPC
0.28
ClinPred
0.034
T
GERP RS
2.7
Varity_R
0.042

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs777893707; hg19: chr3-45588882; API